Clinical trial · Interventional
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer: a Phase II Clinical Study
NCT06552858CI-TRIAL-00079792not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dalpiciclib | Drug | — | UNRESOLVED |
| Fluzoparib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Fluzoparib with Dalpiciclib
- description
- Oral administration of Fluzoparib with Dalpiciclib until disease progression or toxicity intolerance.
- interventionNames
- Drug: Fluzoparib
- Drug: Dalpiciclib
Primary outcomes (1)
- measure
- PFS
- timeFrame
- Two years
- description
- Progression free survival
Secondary outcomes (2)
- measure
- OS
- timeFrame
- Two years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age≥18 years old; 2. Sign the informed consent form; 3. Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer. 4. Tumor recurrence or progression within 6 months after using platinum-based drugs; Exclusion Criteria: 1. Any uncontrolled medical condition that may put the patient at high risk during treatment . 2. Receipt of any other investigational medicinal product within the last 30 days before randomization. 3. Patients with ovarian cancer excluded by pathological or clinical diagnosis; 4. Physical intolerance patients; 5. Patients who are unwilling to participate in the clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.